217 A randomised, concentration-controlled, comparison of standard (5 day) vs prolonged (15 day) infusions of etoposide phosphate in small cell lung cancer (SCLC)

Joel, S.; O’Byrne, Kenneth J.; Penson, R. T.; Papamichael, D.; Higgins, Alexandra; Robertshaw, H.; Rudd, Robin; Talbot, D C; Ml, Slevin

doi:10.1016/s0169-5002(97)89599-2

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The particular finding of concentrationdependent myelotoxicity of etoposide was similar to that in another report. 19 In that study, 15 patients with previously untreated, extensive disease SCLC received single-agent etoposide phosphate by continuous infusion for 15 days. Dosage was based on targeting plasma etoposide concentration to 1 µg/ml.…”

Section: Discussionmentioning

confidence: 99%

Pharmacodynamic Profile of Prolonged Etoposide Administration in Patients with Small Cell Lung Cancer and Non‐Hodgkin's Lymphoma

1999

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacodynamic Profile of Prolonged Etoposide Administration in Patients with Small Cell Lung Cancer and Non‐Hodgkin's Lymphoma

1999

View full text Add to dashboard Cite

show abstract

“…However, when treatment duration was extended to 8 days, no additional benefit was seen compared with 5 days, 1 and a 15-day infusion study had to be stopped early because of a worse response in the 15-day arm. 11 Thompson et al performed a study using a protracted intravenous infusion of etoposide. This study, carried out in patients with potentially etoposide-sensitive malignancies, was performed at doses of 18-25 mg mday -1 for 21-153 days.…”

Section: Introductionmentioning

confidence: 99%

A Phase I/II Study of a 72‐h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma

Crawley

Judson

Verrill

et al. 1997

Sarcoma

View full text Add to dashboard Cite

Purpose. The study was performed to assess the antitumour activity and toxicity of a 72-h continuous infusion of single-agent etoposide as second-line treatment for patients with locally advanced or metastatic soft tissue sarcoma (STS), following reports of substantial activity using this schedule of etoposide administration as first-line treatment in combination with ifosfamide.Patients/method. This was an open phase I/II trial performed at a single institution in patients with metastatic or locally advanced STS who had failed first-line treatment with doxorubicin + ifosfamide combination chemotherapy or, less commonly, single-agent treatment with doxorubicin or ifosfamide. Etoposide was given as a continuous intravenous infusion over 72 h. The starting dose level was 200 mg m(-2) day(-1) x 3 escalating in 10% steps in cohorts of three patients until dose-limiting toxicity was encountered.Results. Seventeen patients were treated, median age 47 years (range 26-71 years). No responses were seen in 16 assessable patients despite etoposide levels in the cotoxic range. The steady-state plasma concentration exceeded 8 mug ml-(1) in all patients and in patients treated at >/= 600 mg m -(2) the mean steady-state level was 14.4 mug ml -(1). The median event-free survival was 6 weeks (95% confidence interval (CI) 3.31-8.69) and the overall survival 16 weeks (95% CI 9.28-22.72). The maximum tolerated dose in this pretreated patient group was 200 mg mm(-2) day(-1) x 3. The dose-limiting toxicity was myelosuppression.Discussion. Etoposide given by 72-h infusion is inactive as second-line chemotherapy in STS. It is associated with significant toxicity when given in these doses, in this patient group.

show abstract

217 A randomised, concentration-controlled, comparison of standard (5 day) vs prolonged (15 day) infusions of etoposide phosphate in small cell lung cancer (SCLC)

Cited by 2 publications

References 0 publications

Pharmacodynamic Profile of Prolonged Etoposide Administration in Patients with Small Cell Lung Cancer and Non‐Hodgkin's Lymphoma

Pharmacodynamic Profile of Prolonged Etoposide Administration in Patients with Small Cell Lung Cancer and Non‐Hodgkin's Lymphoma

A Phase I/II Study of a 72‐h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma

Contact Info

Product

Resources

About